Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.54 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.54 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 6/20 | 0.46 |
| ▸ | AMY2A | P04746 | 1/20 | 0.44 |
| ▸ | GJA1 | P17302 | 1/20 | 0.44 |
| ▸ | GJB2 | P29033 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26211402 | 1.00 | L3MBTL1 (0.57) | L3MBTL1MAPTLGALS8LGALS3LGALS4 | |
| SCHEMBL20998700 | 1.00 | L3MBTL1 (0.57) | L3MBTL1MAPTLGALS8LGALS3LGALS4 | |
| SCHEMBL26211411 | 1.00 | L3MBTL1 (0.57) | L3MBTL1MAPTLGALS8LGALS3LGALS4 | |
| SCHEMBL18608056 | 1.00 | L3MBTL1 (0.57) | L3MBTL1MAPTLGALS8LGALS3LGALS4 | |
| SCHEMBL26211387 | 1.00 | L3MBTL1 (0.57) | L3MBTL1MAPTLGALS8LGALS3LGALS4 | |
| SCHEMBL26211750 | 1.00 | L3MBTL1 (0.57) | L3MBTL1MAPTLGALS8LGALS3LGALS4 | |
| SCHEMBL10089704 | 0.96 | L3MBTL1 (0.54) | L3MBTL1MAPTLGALS8LGALS3LGALS4 | |
| SCHEMBL17618258 | 0.96 | L3MBTL1 (0.54) | L3MBTL1MAPTLGALS8LGALS3LGALS4 | |
| SCHEMBL18680394 | 0.96 | L3MBTL1 (0.54) | L3MBTL1MAPTLGALS8LGALS3LGALS4 | |
| SCHEMBL26192651 | 0.95 | LGALS8 (0.53) | L3MBTL1MAPTLGALS8LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278976-A1 | Synthesis Of Beta-Glycolipid Compounds | GlycoSurf, Inc. | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278976-A1 | Synthesis Of Beta-Glycolipid Compounds | B3GAT3, GALE, HSD17B14 | L3MBTL1 875/4885MAPT 3633/4885LGALS8 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.